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Abstract
Background: Influenza vaccines are reviewed each year, and often changed, in an effort to maintain their effectiveness
against drifted influenza viruses. There is however no regular review of influenza vaccine effectiveness during, or at the end
of, Australian influenza seasons. It is possible to use a case control method to estimate vaccine effectiveness from
surveillance data when all patients in a surveillance system are tested for influenza and their vaccination status is known.
Methodology/Principal Findings: Influenza-like illness (ILI) surveillance is conducted during the influenza season in sentinel
general practices scattered throughout Victoria, Australia. Over five seasons 2003–7, data on age, sex and vaccination status
were collected and nose and throat swabs were offered to patients presenting within three days of the onset of their
symptoms. Swabs were tested using a reverse transcriptase polymerase chain reaction (RT-PCR) test. Those positive for
influenza were sent to the World Health Organization (WHO) Collaborating Centre for Reference and Research on Influenza
where influenza virus culture and strain identification was attempted. We used a retrospective case control design in five
consecutive influenza seasons, and estimated influenza vaccine effectiveness (VE) for patients of all ages to be 53% (95% CI
38–64), but 41% (95% CI 19–57) adjusted for age group and year. The adjusted VE for all adults aged at least 20 years, the
age groups for whom a benefit of vaccination could be shown, was 51% (95% CI 34–63). Comparison of VE estimates with
vaccine and circulating strain matches across the years did not reveal any significant differences.
Conclusions/Significance: These estimates support other field studies of influenza vaccine effectiveness, given that
theoretical considerations suggest that these values may underestimate true effectiveness, depending on test specificity
and the ratio of the influenza ILI attack rate to the non-influenza ILI attack rate. Incomplete recording of vaccination status
and under-representation of children in patients from whom a swab was collected limit the data. Improvements have been
implemented for prospective studies.
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Introduction
Influenza vaccination is required each year because the
predominant circulating strains of the influenza virus drift over
time. The composition of influenza vaccines is reviewed annually
and vaccine constituents are often changed in an effort to maintain
protection against drifted influenza virus strains. In temperate
southern Australia, the influenza season occurs between about
May (late autumn) and October (early spring). The Australian
Influenza Vaccine Committee meets in October of the preceding
year to choose the influenza strains that will be included in the
vaccine. Influenza vaccine is usually available by February or
March of the following year, at least two months, but usually closer
to four months, before the influenza season. Influenza vaccine is
provided free of cost to all adults aged 65 years and over and
adults of Aboriginal and Torres Island descent aged 50 years and
over and is recommended, but not funded, for other groups.
Most countries where influenza vaccine is offered as part of a
publicly funded program do not routinely monitor the success of
vaccine strain selection by monitoring seasonal influenza vaccine
effectiveness (VE). We use the conventional definitions of vaccine
effectiveness as an estimate from an observational study whereas
vaccine efficacy is an estimate derived from a trial. Vaccine
efficacy is defined as the percentage reduction of cases among
vaccinated individuals. Where VE is monitored, it is most
efficiently done using routinely collected data available from
sentinel surveillance networks.[1,2] These VE estimates can be
compared with estimates of efficacy against clinical disease due to
laboratory confirmed influenza from trials and meta-analyses.
Published efficacy estimates range from 63% (95% CI 45–70) for
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and 58% (95% CI 26–77) for people aged 60 years and over from
a large randomised controlled trial.[5] However a Cochrane
review concluded that influenza vaccine was not efficacious against
laboratory confirmed influenza in the elderly.[6]
France is unique in using the screening method to monitor
influenza VE as the influenza season unfolds. This allows early
recognition of possible poor vaccine effectiveness.[1] However, to
estimate VE, the screening method requires accurate assessment of
a relatively high vaccination coverage.[7] Often neither of these
conditions is met. It has recently been demonstrated that it is
possible to estimate VE from routine surveillance data using all
patients with an influenza-like illness (ILI) who have presented for
medical attention and have subsequently been tested for
influenza.[8] VE is estimated as 12OR, where OR is the odds
ratio from a case control study. Cases and controls are selected
from the cohort of all patients recruited from an influenza sentinel
surveillance network who present with an ILI. All patients with an
ILI who have been tested for influenza using a standard laboratory
assay are eligible for inclusion in the study. Cases are ILI patients
with laboratory confirmed influenza and controls are ILI patients
without laboratory confirmed influenza. Controls may have
another respiratory virus or no virus detected. We aimed to
perform a retrospective estimate of influenza VE against medically
attended laboratory confirmed influenza for five influenza seasons
between 2003 and 2007 in Victoria, Australia. We used the ILI
case control design and data collected routinely from seasonal
sentinel surveillance. We also compared annual estimates of VE
with a review of the match between the circulating and vaccine
strains for each season.
Materials and Methods
Routine sentinel surveillance
Victoria is a southern Australian state with a temperate climate.
The influenza season occurs in winter and often extends into the
early months of spring. Between May and September each year,
sentinel surveillance is conducted in general practices scattered
throughout Melbourne and regional Victoria. Victoria’s popula-
tion is approaching 5 million, with 3.85 million people living in the
state capital, Melbourne. Laboratory supported surveillance began
in 1998 [9] and surveillance reports are published annually
(available at http://www.cdc.gov/ncidod/eid/vol1no1/longbotm.
htm). For each season, participating general practitioners (GPs)
were asked to report weekly on the total number of consultations
and any patients presenting with ILI, defined as history of fever,
cough and fatigue/malaise.[10] Once formal consent was
obtained from these patients, GPs collected data on their age,
sex, symptoms and vaccination status. Nose and throat swabs were
offered to patients presenting within three days of the onset of their
symptoms. Swabs, pooled in a single vial of viral transport
medium, were transported by courier to the Victorian Infectious
Diseases Reference Laboratory (VIDRL) where they were tested
using an in-house respiratory multiplex reverse transcriptase
polymerase chain reaction (RT-PCR) test identifying influenza
viruses, adenoviruses, picornaviruses (enteroviruses and rhinovi-
ruses), respiratory syncytial virus and parainfluenza viruses.[11] All
nose and throat swabs from sentinel ILI patients were stored at
270uC and those that were positive for influenza were transported
frozen to the World Health Organization (WHO) Collaborating
Centre for Reference and Research on Influenza where influenza
virus culture and strain identification was attempted.
Written consent was obtained from patients at the time a swab
was taken, indicating that aggregate anonymous data will be used
for surveillance purposes and influenza positive results will be
notified to the state government Department of Human Services,
Victoria. Laboratory confirmed influenza has been a gazetted
notifiable disease in Victoria since 2001. Because of the legal
requirement for the laboratory to notify positive cases, we have
been advised by the Victorian Department of Human Services
that formal ethics approval is not required for the surveillance
program.
Seasonal thresholds were based on rates of ILI cases per 1000
consultations. Baseline activity, normal seasonal and higher than
expected seasonal activity were defined as below 2.5, between 2.5
and ,15, and between 15 and ,35 per 1000 consultations,
respectively. According to these thresholds, ‘epidemic influenza
activity’ was defined by rates at or above 35 cases per 1000
consultations.[12]
Estimation of VE
We restricted our analysis to patients who presented for medical
attention at any of the sentinel surveillance sites and who
subsequently had a swab taken for the identification of influenza
virus by RT-PCR. Patients whose PCR tests were inhibited were
excluded from the analysis, as were patients whose vaccine status
or age was unknown. We examined the proportion of cases and
controls with unknown vaccination status and also examined
unknown vaccination status by age group. Counting all patients
whose swabs were positive for influenza virus RNA as cases and all
other patients whose swabs were negative or positive for another
respiratory virus as controls, we estimated unadjusted
VE=12OR, where OR is the odds of being a vaccinated case
divided by the odds of being a vaccinated control. We report only
the OR when there is no apparent protective effect of vaccination.
We performed an age-adjusted estimate of VE by logistic
regression using the following age groups: 0–4 years, 5–19 years,
20–49 years, 50–64 years and 65 years and above. We also
adjusted for year. We examined homogeneity by age group and
year using the Mantel-Haenszel test for homogeneity. We tested
whether the estimates of VE were significantly different by testing
whether the difference between the natural logarithms of the ORs
differed from zero, where the standard error (SE) of ln OR12ln
OR2 was calculated as the square root of [SE (ln OR1)
2+SE (ln
OR2)
2]. Two-sided p-values for the null hypothesis were obtained
from the Normal distribution. The 5% significance level was used
for all comparisons. Surveillance data were maintained in a
purpose designed database (SL Digital) and data were exported
from this database to STATA 10 [13] for all statistical analyses.
Analysis of circulating and vaccine strains
Influenza viruses were received by the WHO Collaborating
Centre for Reference and Research on Influenza from the
surveillance program at VIDRL and from other laboratories in
Melbourne. Viruses were received as isolates, passaged in cell
culture, or as original clinical samples in which influenza A or B
antigen had been detected by immunofluorescence or RNA
detected by RT-PCR. Once received at the Centre, the isolates or
samples were cultured in MDCK cells (CCL-34, ATCC, USA)
and monitored for growth by cytopathic effect and the presence of
haemagglutinating activity using Turkey red blood cells as
previously described.[14] Positive samples were typed using the
haemagglutination inhibition assay (HI) against a panel of known
standard reference viruses (including vaccine strains) and their
homologous ferret antisera.[14] Prior to use, ferret antisera were
pre-treated with receptor destroying enzyme (RDE) (Denka
Seikan, Japan), to remove non-specific inhibitors. Viruses were
considered to be vaccine-like if their HI titre was no more than 4-
Flu Vaccine Effectiveness
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were those selected by the Australian Influenza Vaccine
Committee and approved by the Therapeutics and Goods
Administration (TGA) for use in Australia each year (http://
www.tga.gov.au/committee/aivc.htm). The proportion of each
influenza type/subtype circulating was obtained from the total
influenza viruses isolated at the WHO Influenza Centre in
Melbourne from Victorian patients in each calendar year.
Results
Influenza seasons and ILI patients
The number of GPs participating in sentinel surveillance ranged
from 65 to 79 for each of the five influenza seasons and GPs
recorded 5,000 ILI consultations from a total of more than
700,000 consultations (Table 1).
The five influenza seasons included in the VE assessment were
characterised by higher than expected seasonal activity in 2003
and 2007 and normal seasonal activity in the other three years.
Earlier surveillance years, not included in the study of VE, have
been included for comparison of relative influenza activity
(Figure 1). The age distribution of ILI patients for whom a nose
and throat swab was collected was similar in all years and is
shown, compared with the age distribution of all patients recorded
as attending a sentinel practice with an ILI (Figure 2). In all five
influenza seasons, 71% of ILI patients were aged 20–64 years.
Patients with an ILI aged less than 19 years accounted for 23% of
all patients seen and those aged 65 years and above comprised 7%.
Swabs were taken from approximately 40% (2065/5000) of the
ILI patients seen by sentinel surveillance GPs. Laboratory results
were considered for 2015 patients (15 patients were excluded as
age was unknown and 35 were excluded as the PCR test was
inhibited). Vaccination status was known for 73% (n=1479/2015)
of the patients with laboratory results, ranging from 65–80% over
the five influenza seasons. Influenza virus was detected from an
average of 36% (range 18–47) of all ILI patients with a laboratory
result over the five seasons. Other viruses accounted for ILI in an
average of another 16% (range 10–29) of patients (Table 2).
VE estimates compared with circulating and vaccine
strains
VE estimates were calculated for the 1479 patients for whom
age, laboratory results, and vaccination status data were available.
The unadjusted estimate of VE for each of the five seasons ranged
from 39% (95% CI 219 to 67) to 64% (95% CI 9–86) and, for the
five seasons combined, was 53% (95% CI 38–64) (Table 3).
Vaccination status was unknown for 27% (536/2015) of
patients, 24% (181/741) for cases and 28% (355/1274) for
Table 1. General practitioners, ILI consultations and total
consultations, Victorian sentinel influenza surveillance, 2003–
2007.
Year
Sentinel
practitioners
ILI
consultations
Total
consultations
2003 79 1283 156,445
2004 76 820 166,626
2005 74 1087 149,018
2006 74 765 136,732
2007 65 1045 120,256
doi:10.1371/journal.pone.0005079.t001
Figure 1. Influenza-like illness 1997 to 2007 from general practice sentinel surveillance.
doi:10.1371/journal.pone.0005079.g001
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proportion of patients with unknown vaccination status by age
group. Vaccination status was unknown for 34% of 0–4 years, and
25–27% of all other age groups (p=0.6).
When VE estimates were adjusted for age and year they
declined. The age and year adjusted estimate of VE for the five
seasons combined was 41% (95% CI 19–57). Homogeneity by
sub-group could not be rejected for year (p=0.89) but lack of
homogeneity was suggested by age group (p=0.07). We therefore
report results by age group over the five years. In this period the
OR could not be calculated for children aged 0–4 years, as there
were no vaccinated children without influenza. This age group
comprised only 2% (48/2015) of patients with laboratory testing.
There was no apparent protection for older children and young
adults aged 5–19 years (OR=1.6, 95% CI 0.6–4.9). However
moderate to good protection was seen for adults aged 20–49 and
50–64 years with VE estimates adjusted for year equal to 42%
(95% CI 13–61) and 57% (95% CI 17–78) respectively. For these
two age groups combined, the age and year adjusted VE was 46%
(95% CI 26–62). In all five seasons, influenza virus was detected in
26/99 patients aged 65 years and over and VE adjusted for year
was estimated as 69% (95% CI 8–90). There were no significant
differences in VE estimates for any of the three adult age groups.
The age group and year adjusted VE for all adults aged at least 20
years was 51% (95% CI 34–63).
Vaccination status and the proportion of patients with
laboratory confirmed influenza differed significantly by age group.
We compared patients aged 0–19, for whom no benefit of
Figure 2. Laboratory confirmed influenza and ILI cases by proportion of age group, 2003–2007.
doi:10.1371/journal.pone.0005079.g002
Table 2. Sampled ILI patients with influenza or another respiratory virus detected, by vaccination status, Victoria 2003–2007.
Year N tested Vaccinated Unvaccinated Unknown
n
Influenza
detected
(% of n)
Other
respiratory virus
detected (%) n
Influenza
detected
(% of n)
Other
respiratory virus
detected (%) n
Influenza
detected
(% of n)
Other
respiratory virus
detected (%)
2003 535 87 23 (26%) 13 (15%) 263 104 (40%) 22 (8.4%) 185 56 (30%) 21 (11%)
2004 265 61 6 (9.8%) 19 (31%) 137 32 (23%) 37 (27%) 67 10 (15%) 21 (31%)
2005 397 63 18 (29%) 16 (25%) 244 116 (48%) 28 (11%) 90 46 (51%) 18 (20%)
2006 381 54 14 (26%) 9 (17%) 222 81 (36%) 34 (15%) 105 31 (30%) 19 (18%)
2007 437 79 26 (33%) 13 (16%) 269 140 (52%) 35 (13%) 89 38 (43%) 14 (16%)
All 2015 344 87 (25%) 70 (20%) 1135 473 (42%) 156 (14%) 536 181 (34%) 93 (17%)
doi:10.1371/journal.pone.0005079.t002
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(19/329) of patients aged 0–19 were vaccinated compared with
28% (325/1150) of older patients (p,0.001). For those aged 65
years and over, who were eligible for free vaccine, the proportion
vaccinated was 82% (82/99). Of younger patients, 53% (173/329)
tested positive for influenza compared with 34% (387/1150) of
older patients (p,0.001).
Comparison of VE estimates with vaccine and circulating
strains is shown in Table 3 for each of the five influenza seasons. In
2003 more than 99% of all circulating virus strains in Victoria
were A/Fujian/411/2002 (H3N2)-like, but the corresponding
vaccine strain was A/Moscow/10/99. In that year the age
adjusted VE was 40% (95% CI 213 to 68). The following year
there was an exact match between the H3 vaccine and circulating
strains (Fujian). Although the H3 sub-type comprised only about
63% of circulating strains, the remainder of which were influenza
B with mismatch between vaccine and circulating strains, the age
adjusted VE estimate in this year was 52% (95% CI 228 to 82).
However this estimate was based only on 38 ILI patients with
laboratory confirmed influenza (Table 2). In 2005 when
circulating strains were spread between influenza H1, H3 and B
with good vaccine strain match, influenza VE was estimated as
34% (95% CI 233 to 67). Reflecting some H3 mismatch in 2006,
the VE estimate was lower at 16% (95% CI 277 to 60) in a season
again characterised by influenza H3 and B. Despite apparent
mismatches with H1, H3 and B in 2007, all of which were
circulating, the VE estimate was 54% (95% CI 15–75).
Discussion
Usingroutinelycollectedsurveillance data,wehaveshownanage
and year adjusted estimate of influenza VE of 41% (95% CI 19–57)
over five consecutive seasons for all age groups but 51% (95% CI
34–63) for adults aged at least 20 years, for whom a benefit of
vaccination could be shown. In the sample of patients from our
surveillance system there was no apparent protective effect for age
groups under 19 years and influenza VE estimates were non-
significantly higher for adults aged 50–64 and 65 years and over
compared with adults aged 20–49 years. We were unable to show
any difference in VE in the years when the vaccine strains were well
matched compared with years when the match was poorer. A non-
significant tendency for VE estimates to be lower in years with an
H3 mismatch was seen in 2003 and 2006 but not in 2007.
There are a number of issues that impact on the VE estimates
obtained. The small number of patients and low vaccination rates
in the younger age groups indicates that our sentinel surveillance
system is better suited to estimating VE amongst working age
adults who comprised almost three quarters of our surveillance
population. Theoretical considerations suggest that the ILI case
control method for estimating VE from surveillance data may
Table 3. Estimates of influenza vaccine effectiveness (VE) with vaccine and circulating strains.
Year
Vaccine
effectiveness
(95% CI)
Age adjusted
vaccine effectiveness
(95% CI)
Type/
subtype
% type/subtype
in that year in
Victoria
Vaccine strain (or
like strain) used/
recommended
Most commonly circulating
like-strain(s) in Victoria
2003 45 (6 , 68) 40 (213 , 68) A(H1) 0 A/New Caledonia/20/99 -
A(H3) 99.5 A/Moscow/10/99
1 A/Fujian/411/2002 (H3N2)
B 0.5 B/Hong Kong/330/2001
2*
2004 64 (9 , 86) 52 (228 , 82) A(H1) 0 A/New Caledonia/20/99 -
A(H3) 62.8 A/Fujian/411/2002 A/Fujian/411/2002 (H3N2)
B 37.2 B/Hong Kong/330/2001
2* B/Shanghai/361/2002
+
2005 56 (19 , 76) 34 (233 , 67) A(H1) 36.8 A/New Caledonia/20/99 A/New Caledonia/20/99 (H1N1)
A(H3) 44.8 A/Wellington/1/2004 A/Wellington/1/2004 and A/
California/7/2004 (H3N2)
B 18.4 B/Shanghai/361/2002
3+ B/Shanghai/361/2002
+ and B/
Hong Kong/330/2001
*
2006 39 (219 , 67) 16 (277 , 60) A(H1) 2.1 A/New Caledonia/20/99 -
A(H3) 67.2 A/California/7/2004
4 A/Wisconsin/67/2005 (H3N2)
B 30.7 B/Malaysia/2506/2004
* B/Malaysia/2506/2004
2007 55 (23 , 73) 54 (15 , 75) A(H1) 36.6 A/New Caledonia/20/99 A/Brisbane/59/2007 (H1N1)
A(H3) 50.0 A/Wisconsin/67/2005 A/Brisbane/10/2007 (H3N2)
B 13.4 B/Malaysia/2506/2004* B/Florida/4/2006
+
1Actual vaccine strain used A/Panama/2007/99.
2Actual vaccine strain used B/Shangdong/7/97 or B/Brisbane/32/2002.
3Actual vaccine strain used B/Jiangsu/10/2003.
4Actual vaccine strain used A/New York/55/2004.
*B/Victoria/2/87-lineage.
+B/Yamagata/16/88-lineage.
doi:10.1371/journal.pone.0005079.t003
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the ratio of the influenza ILI attack rate to the non-influenza ILI
attack rate.[8] However the specificity of the PCR assay used in
this study has been estimated as 100% for influenza A and B [11],
so that the major impact of study design on subsequent VE
estimate will be the ratio of the influenza ILI attack rate to the
non-influenza ILI attack rate. This impact is modeled to be
minimal for high test specificity (Figure 3, [8]), so that study design
should not have had a major effect on VE estimates. The various
mismatches between circulating and vaccine strains may have led
to lower than expected estimates of VE.
Age was a confounder in our estimates of VE. Compared to all
older age groups, a higher proportion of the sample of children
and younger adults aged 0–19 years tested influenza positive but a
lower proportion was vaccinated. This resulted in a fall in VE
estimates when adjusted for age.
Comprehensive recording of vaccine status remains an issue in
our surveillance network but is not likely to have had a significant
effect on our estimate of VE. In the Canadian study [2], vaccine
status was unknown for only 13/524 (2%) of patients compared
with 27% in this study. However we have demonstrated no
significant difference in unknown vaccination status by case/
control status (outcome) or age group (confounder). Missing
vaccination status should therefore have no significant effect on the
estimate of VE. Improvements have been implemented in the
ascertainment of vaccination status for prospective studies.
Our summary VE estimate is lower than that obtained in
Canada for the 2005–6 season when there was a dual A and B
mismatch. Using the same study design as reported here, the
unadjusted VE estimate for influenza A or B from the Canadian
study was 65% (95% CI 42–79), falling to 58% (95% CI 24–76)
when adjusted for age but rising again to 61% (95% CI 26–79)
when adjusted for age and chronic conditions.[2] Our VE estimate
also fell when adjusted for age. We do not routinely collect
information on co-morbidities and therefore could not adjust for
these conditions.
We did not estimate VE separately for subtype because our
subtype data were incomplete over the 5 years. VE estimates by
subtype can be used to further evaluate vaccine strain selection but
it is the summary VE estimate that is published in meta-analyses
[4] and used in studies attempting to establish the cost effectiveness
of influenza vaccine.[15,16] The summary estimate is of most
interest to policy makers, although it should be recognised that this
estimate attempts to capture VE for influenza B, H1 and H3,
circulating in different proportions at different thresholds, and
with varying circulating and vaccine strain mismatch in each
season.
Using the screening method to estimate field VE, based on data
from the French sentinel practice network to estimate the
proportion of patients vaccinated and population surveys to
estimate the proportion of the population vaccinated, estimates of
VE against ILI ranged from 42% (95% CI 31–51) to 76% (95% CI
68–81) for patients aged 15–64 years but were lower for patients
aged 65 years and above.[1] In our population estimates of VE
against laboratory confirmed influenza were higher in patients
aged 65 years and above but we had too few patients aged 65 years
and above to report VE by year in this age group. If this difference
in VE is not explained by sampling error, an apparent higher VE
in older people may represent a more healthy population of
ambulatory older people being seen in general practice, with more
at-risk patients attending hospitals or being seen by GPs in aged-
care facilities. Obtaining co-morbidity data for patients may assist
in understanding these findings.
In using surveillance data for research purposes, it would be
ideal if sentinel practices were representative of all general
practices. We have previously demonstrated that our sentinel
network adequately describes ILI activity in Victoria.[17]
However, we know that ILI patients from whom a nose and
throat swab are taken, are not representative of all ILI patients or
of all patients notified with influenza. Children were under-
represented in patients from whom a swab was collected in the
sentinel practices (Figure 2).
Despite its limitations, we have demonstrated that the Victorian
sentinel surveillance network is able to provide estimates of
influenza VE. We have further compared VE estimates with
vaccine and circulating strain matches and, while there were no
significant differences in VE across the years, there was some
suggestion that VE may be lower in years when the influenza A/
H3N2 subtype is mismatched, perhaps reflecting the fact that
infection with the H3N2 subtype is generally more severe in
adults.[18,19,20] Routine monitoring data of this type will be
further interrogated to add value to the sentinel surveillance of
influenza.
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